PTEN and prostate carcinoma: For example, preclinical studies have shown that the PI3K inhibitor BAY1082439 activates the interferon (IFN) α/γ pathway, increases the expression of C-X-C motif chemokine ligand 10 (CXCL10) and C–C motif chemokine ligand 5 (CCL5), inhibits regulatory T cells, and promotes CD8+ T cell infiltration, thus alleviating immune suppression in PTEN-deficient prostate cancer [121].